NewsRoom Articles - Page 3 of 115 - CanadianCannabisWire

TuesdayMay 14, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation

Lexaria, a global innovator in drug delivery platforms, just announced its newest relationship with the National Research Council of Canada (“NRC”) Specific molecular characteristics of the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, processed with Lexaria’s patented DehydraTECH(TM) technology, will be evaluated Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood compared to Rybelsus(R). This has potential for increased weight-loss and diabetic control Lexaria’s management is confident that this partnership will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year Lexaria Bioscience (NASDAQ: LEXX), a…

ThursdayMay 09, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance

Lexaria has entered an agreement wherein an existing accredited investor has exercised all their warrants to purchase shares The company has received $4.7 million from this undertaking, prior to deducting estimated offering expenses Proceeds fully fund Lexaria’s entire planned 2024 GLP-1 R&D program, leaving additional excess capital for general purposes Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its entry into a warrant exercise agreement with an existing accredited investor to exercise in full certain existing warrants initially issued in October 2023 and February 2024. The warrants will be exercised at $0.97 and $2.185 per…

TuesdayMay 07, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology

Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024 GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings…

MondayApr 22, 2024 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval

Lexaria, a global innovator in drug delivery platforms, has received approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board GLP-1 drugs are utilized in the treatment of type 2 diabetes and obesity, a huge market, and are typically administered by painful and expensive injection, offering a major opportunity for Lexaria’s oral delivery platform This approval sets the company up for dosing within 30 days or less, with tentative study completion dates for this summer The study will comprise two study arms, the second study arm will investigate whether Lexaria’s patented DehydraTECH(TM)-enhanced semaglutide can effectively…

TuesdayApr 16, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Global Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies for 2024

Lexaria, a global innovator in drug delivery platforms, has added three new patents to its portfolio, bringing the total to 41 Two patents were awarded in the U.S., while the third was awarded in Japan, expiring in 2042 and 2041, respectively, if not extended Lexaria’s management plans to maintain focus on GLP-1 studies for 2024 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in the month of April 2024, added three new patents to its portfolio. This brings the total number of awarded patents globally to 41, a testament to the versatility of its patented DehydraTECH(TM) technology…

ThursdayApr 11, 2024 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment

Lexaria, a global innovator in drug delivery platforms, has announced the appointment of Nelson Cabatuan, CPA, as its new CFO Nelson will lend over 15 years of experience in corporate finance and operations, having worked in key organizations within the industry, and will play an integral role in supporting upcoming GLP-1 human clinical studies and overseeing key financial areas of the company The appointment highlights Lexaria’s confidence in its recently confirmed focus on important GLP-1 studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the appointment of Nelson Cabatuan, CPA, as its new Chief Financial…

MondayMar 25, 2024 12:45 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires Contract Research Organization to Perform Important GLP-1 Human Pilot Study

Lexaria, a global innovator in drug delivery platforms, recently hired a Contract Research Organization to perform their second GLP-1 human pilot study which will test a dissolvable DehydraTECH-GLP-1 oral dose formulation The announcement follows Lexaria’s WEIGHT-A24-1 animal study announcement examining diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and cannabidiol alone and in combination The move aligns with the company’s resolve to focus on their ability to enhance the delivery of GLP-1 diabetes and obesity drugs At the beginning of the year, Lexaria Bioscience (NASDAQ: LEXX), a global innovator for enhanced drug delivery platforms, announced its intention to double down…

ThursdayMar 21, 2024 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Achieves 7% Weight Loss; Sets Stage for 8-week Diabetes and Weight Loss Animal Study

Lexaria, a global innovator in drug delivery platforms, highlighted results from its DIAB-A22-1 animal study, highlighting a 7% reduction in weight and a 19.9% reduction in blood glucose With this success, Lexaria looks to kick off its WEIGHT-A24-1 animal study to examine diabetes and weight loss effects of its patented DehydraTECH(TM)-processed GLP-1 drugs and DehydraTECH-processed CBD The study will comprise 12 arms and involve 72 animals. It will run for a total of 12 weeks This study will build on previous studies that evidenced DehydraTECH’s potential to enable greater penetration of GLP-1 drugs into the brain tissue Lexaria Bioscience (NASDAQ:…

MondayMar 18, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Huge 2024 Milestone with FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria, a global innovator in drug delivery platforms, recently received FDA clearance for its HYPER-H23-1 clinical study John Docherty, President of Lexaria, has regarded this milestone as a demonstration of its patented DehydraTECH(TM) technology’s overall viability, particularly in the potential treatment of hypertension With HYPER-H23-1, Lexaria looks to build on the success of its previous human clinical studies, whose results have been overwhelmingly positive This marks a considerable milestone even as the company looks to double down on GLP-1 studies for the 2024 calendar year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the…

FridayMar 08, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth

Lexaria, a global innovator in drug delivery platforms, has, since 2016, proven its patented DehydraTECH(TM) technology, asserting its superiority in improving drug bioavailability This has earned it 39 granted patents, with many pending globally DehydraTECH has a number of potential pharmaceutical applications with successful early stage results in hypertension, diabetes and weight loss and many others With its focus on GLP-1 clinical studies for 2024, Lexaria looks to carve out greater market share to make 2024 its biggest year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been pushing the envelope and redefining drug delivery technology.…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 512.354.7000